Results 341 to 350 of about 3,443,356 (396)

Real‐world prevalence of PD‐L1 positivity in early‐stage/metastatic triple‐negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study

Histopathology, Volume 88, Issue 7, Page 1373-1384, June 2026.
In the real‐world VANESSA study in triple‐negative breast cancer, PD‐L1‐positive prevalence was 38% in early‐stage and 20% in metastatic tumours, lower than in prospective trials. The lower prevalence in smaller versus larger tissue samples and by local versus central assessment underlines the importance of robust PD‐L1 testing to determine eligibility
Corrado D'Arrigo, Sitki Tuzlali, Romualdo Barroso‐Sousa, Nagi S El Saghir, Rebecca Dent, Nataša Medić‐Milijić, Gyungyub Gong, Shahin Sayed, Tu Thai Anh, Alisan Zirtiloglu, Götz Hartleben, Paula Toro, Iman Estaytieh, Enya Weber, Regula Deurloo, João Mouta, Lazar Popovic   +16 more
wiley   +1 more source

PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-analysis. [PDF]

Eur Urol Open Sci
Li Y, Li Z, Lu H, Shi P, Liu Y, Liu L, Chen K.   +6 more
europepmc   +1 more source

Hypoxia-related signatures predicts survival, immunosuppression and PARP inhibitor resistance in HCC. [PDF]

Discov Oncol
Su M, Duan H, Gu Y, Zhao J.
europepmc   +1 more source

Comparative characteristics of the effectiveness of therapy with PARP inhibitor in patients with primary ovarian cancer in the Tyumen Region in the period from 2019 to 2023

M. Ya. Kuzmenko, Valeria V. Zhdanova, В. И. Павлова, M. S. Shvedskiy   +3 more
openalex   +2 more sources

PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7. [PDF]

NAR Cancer
Colón-Ríos DA, Dow J, Krysztofiak A, Liu Y, Rogers FA, Glazer PM.   +5 more
europepmc   +1 more source

'Where is my gap': mechanisms underpinning PARP inhibitor sensitivity in cancer. [PDF]

Biochem Soc Trans
Buckley-Benbow L, Agnarelli A, Bellelli R.   +2 more
europepmc   +1 more source

PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis.

JAMA Netw Open
Petousis S, Kahramanoglu I, Appenzeller-Herzog C, Angeles MA, Margioula-Siarkou C, Kacperczyk-Bartnik J, Bilir E, Chatzakis C, Caruso G, Bizzarri N, Dinas K, Bowtell DDL, Garsed DW, Ray-Coquard I, Ledermann JA, Friedlander M, Sotiriadis A, Heinzelmann-Schwarz V, Zwimpfer TA.   +18 more
europepmc   +1 more source

Identification and validation of the PARP inhibitor-related gene KANK3 for predicting prognosis and immunotherapeutic response in prostate cancer. [PDF]

J Cancer
Zhao Y, Wang Q, Qin X, Jiang W, Li H, Xu M, Li X, Ye H, Zhou J, Chen X, Wu G.   +10 more
europepmc   +1 more source

Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistance. [PDF]

Nucleic Acids Res
McGehee CD, Meng XW, Wu X, Correia C, Venkatachalam A, Flatten KS, Peterson KL, Patel AG, Rossman OK, Wong C, Hurley RM, Wagner JM, Schneider PA, Dai H, Poirier GG, Hendrickson AEW, Swisher EM, Pandey A, Li H, Kaufmann SH.   +19 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tackling PARP inhibitor resistance.

Trends in Cancer, 2021
Homologous recombination-deficient (HRD) tumours, including those harbouring mutations in the BRCA genes, are hypersensitive to treatment with inhibitors of poly(ADP-ribose) polymerase (PARPis).
Kasper Fugger, Graeme Hewitt, S. West, S. Boulton   +3 more
semanticscholar   +4 more sources